| Literature DB >> 32650580 |
Neda S Akhavan1,2, Shirin Pourafshar2,3, Sarah A Johnson4, Elizabeth M Foley1,2, Kelli S George2,5, Joseph Munoz1,2, Shalom Siebert1,2, Elizabeth A Clark1,2, Raedeh Basiri1,2, Robert C Hickner1, Negin Navaei2,6, Cathy W Levenson7, Lynn B Panton1,2,8, Bruce P Daggy1, Bahram H Arjmandi1,2,8.
Abstract
Type 2 diabetes (T2D) is a major contributor to morbidity and mortality largely due to increased cardiovascular disease risk. This study examined the relationships among protein consumption and sources on glycemic control and cardiovascular health in individuals with prediabetes and T2D. Sixty-two overweight or obese participants with prediabetes or T2D, aged 45-75 years were stratified into the following three groups based on protein intake: <0.8 g (gram)/kg (kilogram) body weight (bw), ≥0.8 but <1.0 g/kg bw, and ≥1.0 g/kg bw as below, meeting, and above the recommended levels of protein intake, respectively. Body mass, body mass index (BMI), hip circumference (HC), waist circumference (WC), lean mass, and fat mass (FM) were significantly higher in participants who consumed below the recommended level of protein intake as compared with other groups. Higher animal protein intake was associated with greater insulin secretion and lower triglycerides (TG). Total, low-density, and high-density cholesterol were significantly higher in participants who met the recommended protein intake as compared with the other groups. These data suggest that high protein consumption is associated with lower BMI, HC, WC, and FM, and can improve insulin resistance without affecting lipid profiles in this population. Furthermore, higher intake of animal protein can improve β-cell function and lower plasma TG.Entities:
Keywords: RDA; cardiovascular risk factors; diabetes; metabolic syndrome; protein source
Mesh:
Substances:
Year: 2020 PMID: 32650580 PMCID: PMC7400940 DOI: 10.3390/nu12072031
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Figure 1Study flowchart of recruitment and enrolment flowchart. Participants were excluded if they did not meet the inclusion criteria from questions over the phone or from on-site physical assessments and medical history questionnaires, declining participation, or not responding when contacted.
List of medication categories and usage.
| Variable: Medications | Below Recommended Protein ( | Meeting Recommended Protein ( | Above Recommended Protein ( | Total ( |
|---|---|---|---|---|
| Antihypertensive: | 11 (65) | 9 (41) | 10 (43) | 30 (48) |
| Hyperglycemic: | 9 (53) | 8 (36) | 6 (26) | 23 (37) |
| Lipid Lowering: | 6 (35) | 10 (45) | 7 (30) | 23 (37) |
| Hypothyroid: | 3 (18) | 2 (9) | 2 (9) | 7 (11) |
| NSAID: | 0 (0) b | 7 (32) | 3 (13) | 10 (16) |
Values are expressed as n (%) for each group. Abbreviation: NSAID, non-steroidal anti-inflammatory drug. b Denotes significance differences (p ≤ 0.05) from meeting the recommended level of protein intake.
Demographic information and anthropometrics.
| Variable: | Below Recommended | Meeting Recommended | Above Recommended | Total |
|---|---|---|---|---|
| Male/Female ( | 7/10 | 7/15 | 8/15 | 22/40 |
| Pre-DM/ T2D ( | 8/9 | 16/6 | 19/4 | 43/19 |
| Age (years) | 60 ± 1.7 | 63 ± 1.4 | 62 ± 1.4 | 62 ± 0.8 |
| Height (cm) | 164 ± 1.7 | 165 ± 1.4 | 164 ± 1.5 | 165 ± 0.9 |
| Weight (kg) | 95 ± 3.3 c | 89 ± 2.9 c | 76 ± 2.4 | 86 ± 1.9 |
| BMI (kg/m2) | 35 ± 1.3 c | 33 ± 0.9 c | 28 ± 0.9 | 32 ± 0.7 |
| Waist Circumference (cm) | 109 ± 2.7 c | 104 ± 2.3 c | 97 ± 2.5 | 103 ± 1.5 |
| Hip Circumference (cm) | 119 ± 3.3 c | 115 ± 2.1 c | 106 ± 1.8 | 112 ± 1.5 |
| Waist-to-Hip Ratio (cm) | 0.92 ± 0.01 | 0.91 ± 0.02 | 0.92 ± 0.02 | 0.92 ± 0.01 |
| HbA1c (%) | 6.7 ± 0.20 | 6.4 ± 0.23 | 6.2 ± 0.20 | 6.4 ± 0.12 |
| SBP (mmHg) | 132 ± 4.3 | 133 ± 4.0 | 130 ± 2.9 | 131 ± 2.1 |
| DBP (mmHg) | 80 ± 3.0 | 79 ± 1.8 | 77 ± 1.8 | 78 ± 1.2 |
Values reported as mean ± standard error of the mean (SEM). c Denotes significant differences from the above recommended level of protein intake. Abbreviations: BMI, body mass index; HbA1c, hemoglobin A1c; SBP, systolic blood pressure; DBP, diastolic blood pressure; Pre-DM, prediabetic; T2D, type 2 diabetes. c Denotes significant differences (p ≤ 0.05) from the above recommended level of protein intake.
Figure 2Among group differences in weight, body mass index (BMI), waist circumference, hip circumference, and hemoglobin A1c (HbA1c) of study participants below (n = 17), meeting (n = 22), and above (n = 23) the recommended-protein groups (below the recommended-protein group (BRP), the recommended-protein group (RP), and the above recommended-protein group (ARP), respectively). Values are reported as mean ± standard error of the mean (SEM). * Denotes significant differences among groups (p ≤ 0.05).
Nutrient intake.
| Variable: | Below Recommended | Meeting Recommended | Above Recommended | Total |
|---|---|---|---|---|
| Energy Intake (Kcal) | 1627 ± 69 | 2024 ± 105 a | 2163 ± 125 a | 1967 ± 67 |
| Fat (g) | 68 ± 3.6 d | 83 ± 5.6 | 86 ± 7.6 | 80 ± 3.6 |
| Saturated Fat (g) | 23 ± 1.9 | 25 ± 2.4 | 27 ± 2.9 | 25 ± 1.5 |
| Monounsaturated Fat (g) | 7.7 ± 1.3 c | 9.2 ± 1.7 | 12.7 ± 1.7 | 10.1 ± 1.0 |
| Polyunsaturated Fat (g) | 4.6 ± 0.86 c | 4.2 ± 0.75c | 8.1 ± 0.95 | 5.8 ± 0.55 |
| 1.1 ± 0.27 | 1.1 ± 0.27 | 1.3 ± 0.34 | 1.2 ± 0.17 | |
| Cholesterol (mg) | 243 ± 22 | 367 ± 38 a | 411 ± 51 a | 349 ± 25 |
| Carbohydrates (g) | 190 ± 15 c | 234 ± 19 | 253 ± 19 | 228 ± 11 |
| Dietary Fiber (g) | 16 ± 1.5 c | 16 ± 1.5c | 23 ± 2.2 | 19 ± 1.1 |
| Total Sugar (g) | 84 ± 11 | 91 ± 14 | 91 ± 8 | 89 ± 6 |
| Protein (g) | 59 ± 3.5 b, c | 78 ± 2.2 a, c | 97 ± 4.1 a, b | 80 ± 2.7 |
| Animal Protein (g) | 35 ± 2.3 b, c | 51 ± 3.0 a, c | 68 ± 5.9 a, b | 53 ± 3.0 |
| Plant Protein (g) | 21 ± 2.9 c | 22 ± 1.9 c | 32.4 | 26 ± 1.8 |
| Animal/Plant Protein Ratio | 2.2 ± 0.33 | 2.6 ± 0.25 | 2.9 ± 0.43 | 2.6 ± 0.21 |
Values reported as mean ± standard error of the mean (SEM). a Denotes significant differences from below the recommended protein level, b denotes significance differences from meeting the recommended protein level, and c denotes significant differences from above the recommended protein level. d Tends to be significantly (p ≤ 0.1) different as compared with above the recommended protein level. Significance was set at p ≤ 0.05.
Figure 3Among group differences in plant protein, animal protein, and animal-to-plant protein ratio intake from the three-day food record averages of study participants below (n = 17), meeting (n = 22), and above (n = 23) the recommended-protein groups (below recommended-protein group (BRP), recommended-protein group (RP), and above recommended-protein group (ARP), respectively). Values are reported as mean ± standard error of the mean (SEM). * Denotes significant differences among groups (p ≤ 0.05).
Correlations between body mass index, total body fat percentage, and total protein intake with total energy intake.
| Variables: | Total Energy Intake for BRP (kcals) | Total Energy Intake for MRP (kcals) | Total Energy Intake for ARP (kcals) |
|---|---|---|---|
| BMI (kg/m2) | 0.236 | 0.460 * | 0.190 |
| Total Body Fat (g) | 0.302 | 0.416 | 0.161 |
| Protein Intake (g) | 0.372 | 0.505 * | 0.433 |
Values reported as Pearson correlation coefficient (r). Abbreviations: BMI, body mass index. * Denotes significant (p < 0.05) correlations between variables. Correlations were done from the 3-day average of total protein and energy intake of study participants of study participants below (n = 17), meeting (n = 22), and above (n = 23) the recommended protein groups (below recommended-protein group (BRP), recommended-protein group (RP), and above recommended-protein group (ARP), respectively).
Figure 4Correlations between homeostatic model assessment for insulin resistance (HOMA-IR) and homeostatic model assessment for beta-cell function (HOMA-β) with animal-to-plant protein ratio; HDL (high-density lipoprotein) cholesterol with animal and plant protein; triglycerides with animal and plant protein (n = 62). Values are reported as Pearson correlation coefficient (r). * Denotes significant differences among groups (p ≤ 0.05).
Figure 5Among group differences in android fat mass (a), gynoid fat mass (b), total fat mass (c), android lean mass (d), gynoid lean mass (e), total lean mass (f), and fat mass: lean mass ratio (g) of study participants below (n = 17), meeting (n = 22), and above (n = 23) the recommended-protein groups (below recommended-protein group (BRP), recommended-protein group (RP), and above recommended-protein group (ARP), respectively). Values are reported as mean ± SEM. * Denotes significant differences among groups (p ≤ 0.05).
Fasting lipid profile and glycemic control.
| Variable: | Below Recommended | Meeting Recommended | Above Recommended | Total |
|---|---|---|---|---|
| Blood Glucose (mg/dL) | 119 ± 5.7 | 121 ± 6.9 | 116 ± 5.5 | 119 ± 3.5 |
| Total Cholesterol (mg/dL) | 178 ± 8.1 | 212 ± 10 a | 197 ± 7.7 | 197 ± 5.3 |
| LDL-Cholesterol (mg/dL) | 91 ± 8.1 | 130 ± 12 a, c | 103 ± 7.4 | 109 ± 5.8 |
| HDL-Cholesterol (mg/dL) | 46 ± 1.9 | 55 ± 3.3 a | 51 ± 3.0 | 51 ± 1.7 |
| Triglycerides (mg/dL) | 142 ± 13 | 147 ± 12 | 128 ± 12 | 138 ± 7.1 |
| Insulin (uIU/dL) | 17 ± 2.7 | 15 ± 1.8 | 13 ± 1.5 | 15 ± 1.1 |
| Oxidized-LDL (U/L) | 9.3 ± 1.2 | 9.6 ± 0.75 | 8.0 ± 0.63 | 8.9 ± 0.47 |
| HOMA-IR | 5.2 ± 0.94 | 4.5 ± 0.62 | 3.5 ± 0.55 d | 4.3 ± 0.40 |
| HOMA-β | 123 ± 18 | 116 ± 20 | 87 ± 9.8 | 106 ± 9.4 |
Values reported as mean ± SEM. Abbreviations: LDL, low-density lipoprotein; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment for insulin resistance; HOMA-β, homeostatic model assessment for beta-cell function. a Denotes significant differences from below the recommended level of protein intake and c denotes significant differences from above the recommended level of protein intake. d Tends to be significantly (p ≤ 0.1) different as compared with below the recommended level of protein intake.
Figure 6Among group differences in total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, oxidized LDL (Ox-LDL), homeostatic model assessment for insulin resistance (HOMA-IR), and homeostatic model assessment for beta-cell function (HOMA-β) of study participants below (n = 17), meeting (n = 22), and above (n = 23) the recommended-protein groups (BRP, RP, and ARP, respectively). Values are reported as mean ± standard error of the mean (SEM). * Denotes significant differences among groups (p < 0.05).